Sangamo Therapeutics/SGMO

$1.13

0.89%
-
1D1W1MYTD1YMAX

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; TX200, its wholly owned Chimeric Antigen Receptor (CAR), engineered regulatory T cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A., and BIVV003, its zinc finger nuclease, or ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD).

Ticker

SGMO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Alexander Macrae

Employees

478

Headquarters

Richmond, United States

SGMO Metrics

BasicAdvanced
$198.63M
Market cap
-
P/E ratio
-$1.44
EPS
1.37
Beta
-
Dividend rate

What the Analysts think about SGMO

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 6 analysts.
180.53% upside
High $8.00
Low $1.00
$1.13
Current price
$3.17
Average price target

SGMO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,119.35% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$9.3M
36.76%
Net income
$-104.1M
-9.08%
Profit margin
-1,119.35%
-33.52%

SGMO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 84.37%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.32
$0.12
-$0.66
-$0.59
-
Expected
-$0.36
-$0.33
-$0.34
-$0.32
-$0.26
Surprise
-11.11%
-136.57%
92.73%
84.37%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Sangamo Therapeutics stock

Buy or sell Sangamo Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing